CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 2,404 enrolled
Drug / intervention
Meningococcal B +5 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02868970
NCT02868970Phase 4Completed
CompareCT.gov

Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction: A Prospective, Controlled Community Embedded Study With Vaccines With Low Coverage Rates (The Improve ACCESS Study)

Canadian Immunization Research Network·interventional·Posted Aug 16, 2016·Updated Dec 16, 2024

In Brief

A Phase 4 clinical trial evaluating Meningococcal B, High-Dose TIV, and 4 other interventions for Healthy. Completed, enrolled 2,404 participants across 1 site.

Detailed Summary

This project proposes to implement and compare new community pharmacy-based strategies for improving vaccine coverage.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
CollaboratorsGlaxoSmithKline, MCM Vaccines B.V., Canadian Center for Vaccinology, Dalhousie University

Timeline

Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 16, 2016
Enrollment StartFeb 15, 2017
Primary CompletionJul 5, 2021
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 9.9 years ago

Interventions

Meningococcal Bbiological

Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

High-Dose TIVbiological

Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.

Tdap (tetanus-diphtheria-acellular pertussis)biological

Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).

Meningococcal ACWYbiological

Meningococcal ACWY vaccine is indicated for active immunization of individuals up to 55 years of age against invasive meningococcal diseases caused by Neisseria meningitides serogroups A, C, W-135 and Y.

Herpes Zosterbiological

Herpes zoster vaccine is indicated for the immunization of individuals 50 years of age or older for the prevention of herpes zoster (shingles).

Travel Health (Hepatitis A, Hepatitis B, Typhoid Fever)biological

Hepatitis A vaccine is indicated for immunization against infections caused by hepatitis A virus; Hepatitis B vaccine is indicated for immunization against infection caused by hepatitis B virus; and typhoid fever vaccine is indicated for active immunization against Salmonella typhi, the organism which causes typhoid fever.